Hadasit Bio-Holdings Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HSITF research report →
About the company
Hadasit Bio-Holdings Ltd, an Israeli biotechnology enterprise established in Jerusalem in 2005, focuses its efforts on critical therapeutic domains. These include oncology, regenerative medicine, and inflammatory diseases. A key offering is ProtAb, an immunotherapeutic monoclonal antibody engineered to treat autoimmune inflammatory disorders.
- CEO
- Yuval Adar
- IPO
- 2010
- Employees
- 2
- HQ
- Jerusalem, IL
Price Chart
- Market Cap
- $1.33M
- P/E
- -2.71
- P/S
- 0.00
- P/B
- 6.07
- EV/EBITDA
- -5.42
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -152.91%
- ROIC
- -110.63%
- Revenue
- $0 · 0.00%
- Net Income
- $-3,461,000 · 88.14%
- EPS
- $-0.31 · 88.21%
- Op Income
- $-1,702,000
- FCF YoY
- 14.86%
- 52W High
- $0.13
- 52W Low
- $0.12
- 50D MA
- $0.12
- 200D MA
- $0.12
- Beta
- 0.49
- Avg Volume
- 77
Get TickerSpark's AI analysis on HSITF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HSITF coverage
Recent articles, reports, and earnings notes.
No research on HSITF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HSITF report →Similar companies
Peers in the same neighborhood.